Clearly, more studies on the TOP1 mutations that affect these inhibitory SUMOylations are needed to establish a connection between tumor pathogenesis and a dysfunction in the regulation of TOP1 activity in human cells. This evidence concerns the gene TOP1 and neoplasm.